Skip to main content
NCBI home page
Heart logoLink to Heart
. 2005 Jun;91(Suppl 3):iii16–iii19. doi: 10.1136/hrt.2004.058511

Changing roles of anticoagulant and antiplatelet treatment during percutaneous coronary intervention

R Kelly, S Steinhubl
PMCID: PMC1876353  PMID: 15919646

Full Text

The Full Text of this article is available as a PDF (64.9 KB).

Figure 1.

Figure 1

Open in a new tab

 The effect of glycoprotein IIb/IIIa antagonists on 30 day mortality and myocardial infarction in percutaneous coronary intervention.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Armstrong P. W. Heparin in acute coronary disease--requiem for a heavyweight? N Engl J Med. 1997 Aug 14;337(7):492–494. doi: 10.1056/NEJM199708143370710. [DOI] [PubMed] [Google Scholar]
  2. Bertrand M. E., Rupprecht H. J., Urban P., Gershlick A. H., CLASSICS Investigators Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation. 2000 Aug 8;102(6):624–629. doi: 10.1161/01.cir.102.6.624. [DOI] [PubMed] [Google Scholar]
  3. Bhatt Deepak L., Bertrand Michel E., Berger Peter B., L'Allier Philippe L., Moussa Issam, Moses Jeffrey W., Dangas George, Taniuchi Megumi, Lasala John M., Holmes David R. Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J Am Coll Cardiol. 2002 Jan 2;39(1):9–14. doi: 10.1016/s0735-1097(01)01713-2. [DOI] [PubMed] [Google Scholar]
  4. Bhatt Deepak L., Topol Eric J. Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov. 2003 Jan;2(1):15–28. doi: 10.1038/nrd985. [DOI] [PubMed] [Google Scholar]
  5. Choussat Rémi, Montalescot Gilles, Collet Jean Philippe, Vicaut Eric, Ankri Annick, Gallois Vanessa, Drobinski Gérard, Sotirov Ivan, Thomas Daniel. A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention. J Am Coll Cardiol. 2002 Dec 4;40(11):1943–1950. doi: 10.1016/s0735-1097(02)02531-7. [DOI] [PubMed] [Google Scholar]
  6. Ellis S. G., Lincoff A. M., Miller D., Tcheng J. E., Kleiman N. S., Kereiakes D., Califf R., Topol E. J. Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology. EPIC and EPILOG Investigators. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation of PTCA To Improve Long-term Outcome with abciximab GPIIb/IIIa Receptor Blockade. J Am Coll Cardiol. 1998 Nov 15;32(6):1619–1623. doi: 10.1016/s0735-1097(98)00403-3. [DOI] [PubMed] [Google Scholar]
  7. Ferguson James J., Antman Elliott M., Bates Eric R., Cohen Marc, Every Nathan R., Harrington Robert A., Pepine Carl J., Theroux Pierre, NICE-3 Investigators Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study. Am Heart J. 2003 Oct;146(4):628–634. doi: 10.1016/S0002-8703(03)00165-0. [DOI] [PubMed] [Google Scholar]
  8. Grüntzig A. R., Senning A., Siegenthaler W. E. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med. 1979 Jul 12;301(2):61–68. doi: 10.1056/NEJM197907123010201. [DOI] [PubMed] [Google Scholar]
  9. Karvouni Evangelia, Katritsis Demosthenes G., Ioannidis John P. A. Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions. J Am Coll Cardiol. 2003 Jan 1;41(1):26–32. doi: 10.1016/s0735-1097(02)02666-9. [DOI] [PubMed] [Google Scholar]
  10. Kastrati Adnan, Mehilli Julinda, Schühlen Helmut, Dirschinger Josef, Dotzer Franz, ten Berg Jurriën M., Neumann Franz-Josef, Bollwein Hildegard, Volmer Christian, Gawaz Meinrad. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med. 2004 Jan 15;350(3):232–238. doi: 10.1056/NEJMoa031859. [DOI] [PubMed] [Google Scholar]
  11. Lincoff A. Michael, Bittl John A., Harrington Robert A., Feit Frederick, Kleiman Neal S., Jackman J. Daniel, Sarembock Ian J., Cohen David J., Spriggs Douglas, Ebrahimi Ramin. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA. 2003 Feb 19;289(7):853–863. doi: 10.1001/jama.289.7.853. [DOI] [PubMed] [Google Scholar]
  12. Mehta S. R., Yusuf S., Peters R. J., Bertrand M. E., Lewis B. S., Natarajan M. K., Malmberg K., Rupprecht H., Zhao F., Chrolavicius S. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001 Aug 18;358(9281):527–533. doi: 10.1016/s0140-6736(01)05701-4. [DOI] [PubMed] [Google Scholar]
  13. Moore S. A., Steinhubl S. R. Clopidogrel and coronary stenting: what is the next question? J Thromb Thrombolysis. 2000 Oct;10(2):121–126. doi: 10.1023/a:1018706324908. [DOI] [PubMed] [Google Scholar]
  14. Müller I., Seyfarth M., Rüdiger S., Wolf B., Pogatsa-Murray G., Schömig A., Gawaz M. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart. 2001 Jan;85(1):92–93. doi: 10.1136/heart.85.1.92. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Roffi M., Chew D. P., Mukherjee D., Bhatt D. L., White J. A., Heeschen C., Hamm C. W., Moliterno D. J., Califf R. M., White H. D. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation. 2001 Dec 4;104(23):2767–2771. doi: 10.1161/hc4801.100029. [DOI] [PubMed] [Google Scholar]
  16. Roffi Marco, Mukherjee Debabrata, Chew Derek P., Bhatt Deepak L., Cho Leslie, Robbins Mark A., Ziada Khaled M., Brennan Danielle M., Ellis Stephen G., Topol Eric J. Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: a pooled analysis of five randomized clinical trials. Circulation. 2002 Dec 10;106(24):3063–3067. doi: 10.1161/01.cir.0000041250.89627.a9. [DOI] [PubMed] [Google Scholar]
  17. Schwartz L., Bourassa M. G., Lespérance J., Aldridge H. E., Kazim F., Salvatori V. A., Henderson M., Bonan R., David P. R. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med. 1988 Jun 30;318(26):1714–1719. doi: 10.1056/NEJM198806303182603. [DOI] [PubMed] [Google Scholar]
  18. Steinhubl S. R., Lauer M. S., Mukherjee D. P., Moliterno D. J., Lincoff A. M., Ellis S. G., Topol E. J. The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non-Q-wave myocardial infarctions. J Am Coll Cardiol. 1998 Nov;32(5):1366–1370. doi: 10.1016/s0735-1097(98)00376-3. [DOI] [PubMed] [Google Scholar]
  19. Steinhubl S. R., Topol E. J. Clopidogrel with aspirin is the optimal antiplatelet regimen for intracoronary stenting. J Thromb Thrombolysis. 1999 Jun;7(3):227–231. doi: 10.1023/a:1008981408216. [DOI] [PubMed] [Google Scholar]
  20. Steinhubl Steven R., Berger Peter B., Mann J. Tift, 3rd, Fry Edward T. A., DeLago Augustin, Wilmer Charles, Topol Eric J., CREDO Investigators. Clopidogrel for the Reduction of Events During Observation Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002 Nov 20;288(19):2411–2420. doi: 10.1001/jama.288.19.2411. [DOI] [PubMed] [Google Scholar]
  21. Steinhubl Steven, Berger Peter. What is the role for improved long-term antiplatelet therapy after percutaneous coronary intervention? Am Heart J. 2003 Jun;145(6):971–978. doi: 10.1016/S0002-8703(03)00104-2. [DOI] [PubMed] [Google Scholar]
  22. Storey Robert F., Wilcox Robert G., Heptinstall Stan. Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease. Platelets. 2002 Nov;13(7):407–413. doi: 10.1080/0953710021000024402. [DOI] [PubMed] [Google Scholar]
  23. Topol E. J., Moliterno D. J., Herrmann H. C., Powers E. R., Grines C. L., Cohen D. J., Cohen E. A., Bertrand M., Neumann F. J., Stone G. W. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med. 2001 Jun 21;344(25):1888–1894. doi: 10.1056/NEJM200106213442502. [DOI] [PubMed] [Google Scholar]
  24. Topol Eric J. A guide to therapeutic decision-making in patients with non-ST-segment elevation acute coronary syndromes. J Am Coll Cardiol. 2003 Feb 19;41(4 Suppl ):S123–S129. doi: 10.1016/s0735-1097(02)02689-x. [DOI] [PubMed] [Google Scholar]
  25. Wentzel Jolanda J., Janssen Elbert, Vos Jeroen, Schuurbiers Johan C. H., Krams Rob, Serruys Patrick W., de Feyter Pim J., Slager Cornelis J. Extension of increased atherosclerotic wall thickness into high shear stress regions is associated with loss of compensatory remodeling. Circulation. 2003 Jun 23;108(1):17–23. doi: 10.1161/01.CIR.0000078637.21322.D3. [DOI] [PubMed] [Google Scholar]
  26. White G. H., Liew S. C., Waugh R. C., Stephen M. S., Harris J. P., Kidd J., Sachinwalla T., Yu W., May J. Early outcome and intermediate follow-up of vascular stents in the femoral and popliteal arteries without long-term anticoagulation. J Vasc Surg. 1995 Feb;21(2):270–281. doi: 10.1016/s0741-5214(95)70268-7. [DOI] [PubMed] [Google Scholar]

Articles from Heart are provided here courtesy of BMJ Publishing Group

RESOURCES